Mark Soloway, M.D., FACS
Professor and Chairman
University of Miami School of Medicine
Dr. Soloway attended Northwestern University.  He received his MD from Case Western Reserve University in Cleveland, Ohio.  He received his urology training at University Hospitals of Cleveland.  He spent two years as a clinical associate at the National Cancer Institute, NIH, where he developed an animal model for bladder cancer which is still being used to study this cancer.  He was awarded the Gold Cystoscope Award by the American Urologic Association in 1984.  Dr. Soloway was appointed to his present position as Chairman of the Department of Urology at the University of Miami School of Medicine in 1991, following 16 years as Chief of Urologic Oncology at the University of Tennessee-Memphis Center for the Health Sciences.

Dr. Soloway has authored over 300 articles on prostate, bladder and kidney cancer.  He has been a featured speaker at numerous national and international meetings.  He has popularized the case discussion format as a teaching method in an effort to assimilate scientific data into the clinic setting.Some of Dr. Soloway’s major contributions include the role of periprostatic nerve block for prostate biopsy, technical modifications in prostatectomy for prostate cancer, rationale for intravesical chemotherapy for bladder cancer and a grading scale for bone scans in prostate cancer.  Dr. Soloway was one of the first to identify the efficacy of cisplatin for urothelial cancer and for the additive effect of cisplatin with radiation. Dr. Soloway chaired the International Consultation on Bladder Cancer which was sponsored by the Sociéte Internationale de Urologie (SIU). Over 100 urologists, medical oncologists, pathologists, and radiation oncologists came together to provide guidelines on bladder cancer.
Click here for more information.